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SUMMARY
Background
Dysbiosis is associated with many diseases, including irritable bowel syndrome
(IBS), inﬂammatory bowel diseases (IBD), obesity and diabetes. Potential clinical
impact of imbalance in the intestinal microbiota suggests need for new standar-
dised diagnostic methods to facilitate microbiome proﬁling.
Aim
To develop and validate a novel diagnostic test using faecal samples to proﬁle
the intestinal microbiota and identify and characterise dysbiosis.
Methods
Fifty-four DNA probes targeting ≥300 bacteria on different taxonomic levels were
selected based on ability to distinguish between healthy controls and IBS patients
in faecal samples. Overall, 165 healthy controls (normobiotic reference collection)
were used to develop a dysbiosis model with a bacterial proﬁle and Dysbiosis
Index score output. The model algorithmically assesses faecal bacterial abundance
and proﬁle, and potential clinically relevant deviation in the microbiome from
normobiosis. This model was tested in different samples from healthy volunteers
and IBS and IBD patients (n = 330) to determine the ability to detect dysbiosis.
Results
Validation conﬁrms dysbiosis was detected in 73% of IBS patients, 70% of treatment-
na€ıve IBD patients and 80% of IBD patients in remission, vs. 16% of healthy individ-
uals. Comparison of deep sequencing and the GA-map Dysbiosis Test, (Genetic
Analysis AS, Oslo, Norway) illustrated good agreement in bacterial capture; the latter
showing higher resolution by targeting pre-determined highly relevant bacteria.
Conclusions
The GA-map Dysbiosis Test identiﬁes and characterises dysbiosis in IBS and IBD
patients, and provides insight into a patient’s intestinal microbiota. Evaluating
microbiota as a diagnostic strategy may allow monitoring of prescribed treatment
regimens and improvement in new therapeutic approaches.
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INTRODUCTION
Intestinal microbiota is generally comparable for individ-
uals comprising the general adult population, with recent
evidence supporting the gut microbiota as representing a
healthy state deﬁned as normobiosis.1–3 Notably, devia-
tions from normobiosis can result in a transient or per-
manent microbiotic imbalance known as dysbiosis,
which has been linked to several disorders, including
Crohn’s disease (CD), ulcerative colitis (UC), irritable
bowel syndrome (IBS), obesity, nonalcoholic steatohepa-
titis, and type I and type II diabetes.4–8
Traditionally, evaluation of intestinal microbiota com-
position has been based on breath-testing methods,
small-bowel culture techniques and culture-independent
techniques such as high-throughput next-generation
sequencing.9–11 The use of these methods has signiﬁ-
cantly increased our understanding of the role of gut mic-
robiota in health and disease10; for example, small
intestinal bacterial overgrowth12 and altered intestinal
microbiota13 are implicated in subgroups of patients with
functional bowel disorders. Firm evidence for a causal
role of microbiota composition on disease pathogenesis
has, however, remained elusive due to inherent limita-
tions in the diagnostic methods used. For instance,
breath-testing and culture techniques have not been vali-
dated, the majority of species cannot be cultured with
standard methods, and the effect of potentially confound-
ing polypharmacy has not been thoroughly evalu-
ated.11, 14 Nevertheless, increasing awareness of the
potential clinical impact of imbalance in the intestinal
microbiota has led to a call for new standardised diagnos-
tic methods, such as high-throughput DNA sequencing,
that facilitate proﬁling of the microbiome and possible
differentiation between normobiosis and dysbiosis.15
Analysis of faecal samples from individuals with
dysbiosis is anticipated to enable characterisation of the
bacterial proﬁle associated with different pathological
conditions, thus aiding clinical diagnosis of pathological
conditions and improving therapeutic regimens. Further-
more, detailed sequential proﬁling of intestinal microbi-
ota over the course of a therapeutic regimen may allow
for monitoring of inﬂammatory bowel disease (IBD)
progression16 and the prediction of relapse, for example
in CD.17 The ability to characterise the bacterial proﬁles
both of normobiotic and dysbiotic patients may also
help in evaluating the efﬁcacy and further development
of therapeutic approaches such as faecal microbiota
transplantation (FMT), special diets and use of
probiotics.17–21
In the present publication, a novel diagnostic test
(GA-map Dysbiosis Test, Genetic Analysis AS, Oslo,
Norway) is evaluated that allows mapping of the intesti-
nal microbiota proﬁle for a selected set of bacteria, and
used to identify and characterise dysbiosis in a clinical
setting. The GA-map Dysbiosis Test (GA-test) is based
on advances in DNA proﬁling using probes targeting
variable regions (V3 to V7) of the bacterial 16S rRNA
gene to characterise and identify bacteria present (Fig-
ure 1). The probes comprise a highly selective and spe-
ciﬁc bacterial probe set that is used with a unique
algorithm to facilitate determination of dysbiosis level.
The method provides a rapid, high-throughput analysis
of a large number of individual faecal samples. The
breadth of knowledge gained from microbiome projects
was used to develop a test aimed at characterising dysbi-
osis by deviation from a normobiotic state for use in a
clinical diagnostic setting. For this purpose, the test was
technically documented in accordance with EU require-
ments for an in vitro diagnostic test comprising the fol-
lowing intended use claim: ‘The GA-test is intended to
be used as a gut microbiota DNA analysis tool to iden-
tify and characterise dysbiosis’.
GA-map: 1180 bp
Illumina*: 459 bp
V1 V2 V3 V4 V5 V6 V7 V8 V9
0 bp 1400 bp†
8 22 3 11 10
Figure 1 | Target regions for the GA primer (1180 bp) and the Illumina primer (459 bp) showing variable (orange V1-
V9) and conserved (grey) regions in the bacterial 16S rRNA gene (1400 bp) utilised by the two methods. The
numbers in V3 to V7 denote the number of GA probes targeting each variable region, in total 54 probes. *Illumina
application note; http://res.illumina.com/documents/products/appnotes/appnote_16s_sequencing.pdf. †Position in
E. coli (number of base pairs)40
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MATERIALS AND METHODS
Human samples
Faecal samples were collected from 668 adults (aged 17–
76; 69% women), including controls from healthy volun-
teers (n = 297) and patients with IBS (n = 236) and IBD
(n = 135) (Table 1). Faecal samples were collected from
hospitals in Norway, Sweden, Denmark and Spain
(72%), as well as from workplaces in Oslo, Norway
(28%), in an effort to achieve heterogeneity. The healthy
donors had no clinical signs, symptoms or history of
IBD, IBS or other organic gastrointestinal-related disor-
ders (e.g. colon cancer). Additional demographics are
shown in Table 1, and sample inclusion and exclusion
criteria are summarised in Data S1. The IBS samples
were collected as part of prospective studies that used
Rome II and III diagnostic criteria (depending on collec-
tion site) to identify IBS. The distribution of IBS sub-
types was 44% IBS-diarrhoea, 22% IBS-alternating, 17%
IBS-constipation, 11% IBS-unsubtyped and 4% IBS-
mixed. The diagnosis of IBD was based on clinical pre-
sentation conﬁrmed by colonoscopy. Of the 135 IBD
samples, 80 (59%) were treatment-na€ıve patients and 55
(41%) were IBD patients in remission. The distribution
of IBD types was 62% UC and 38% CD for the treat-
ment-na€ıve group, and 67% UC and 33% CD for the
IBD in remission group. Informed consent was obtained
for all samples along with approval from local scientiﬁc
ethics committees. Samples were collected at home, ofﬁce
or hospital, and frozen within 3–5 days (for faecal sam-
ple collection, storage and processing, see Data S2).
Probe identiﬁcation, selection, in silico and in vitro
testing
To establish and optimise the most applicable bacterial
probeset, data from previous IBD and IBS intestinal mic-
robiota research was compiled based on pre-deﬁned
search criteria (Data S3) to provide >500 bacterial obser-
vations associated with the occurrence of IBD and IBS.
From a combined dataset of 496 16S rRNA gene
sequences (consensus sequence[s] for each species, cho-
sen from all available long 16S rRNA sequences and
puriﬁed to avoid sequences errors) from 269 bacterial
species, probes were designed to cover major bacterial
observations made from the literature. All probes were
designed according to Vebø et al.22 with a minimum
melting temperature (Tm) of 60 °C by the nearest-neigh-
bour method23 for the target group where the nucleotide
30 end of the probe is a cytosine; nontarget group probe
requirements were a Tm of 30 °C or absence of a cyto-
sine as the nucleotide adjacent to the 30 end of the
probe. Each probe was designed to target a bacterial spe-
cies or group, i.e. Faecalibacterium prausnitzii (species),
Lactobacillus (genus), Clostridia (class) and Proteobacte-
ria (phylum), based on their 16S rRNA sequence (V3–
V9). Probes that satisﬁed target detection and nontarget
exclusion in silico were evaluated for cross-labelling, self-
labelling and cross hybridisation before ﬁnal validation
was performed against bacterial strains in vitro.
After in vitro testing, a panel of 124 optimal probes
was further selected using variable selection methods:
variable importance in projection, selectivity ratio and
interval partial least squares using data from a selection
of healthy and IBS samples (data not shown). The vari-
ables (probes) were selected based on their ability to dis-
tinguish between samples isolated from healthy
individuals and IBS patients. A ﬁnal panel of 54 probes
was selected covering the sites across V3 to V7 on the
16S rRNA sequence (Figure 1). Bacterial target speciﬁc-
ity, tested with the 54-probe set against 368 available sin-
gle bacterial strains (Data S4), was performed to deﬁne
the target bacteria for each probe. The probes detect bac-
teria within the six phyla; Firmicutes, Proteobacteria,
Table 1 | Demographic information
Categories Total
Females
(%)
Age (years)*
Mean Range
Healthy controls 297 63 41 21–70
Nordic 254 64 42 21–70
Danish 19 63 42 23–61
Spanish 24 50 35 22–56
IBS† 236 78 40 17–76
IBS-D 102 79 40 18–70
IBS-C 41 85 42 22–73
IBS-M 10 80 37 19–55
IBS-U 25 88 41 19–68
IBS-A 51 67 39 20–62
IBD treatment-na€ıve 80 56 34 18–61
CD 30 50 33 19–53
UC 50 63 35 18–61
IBD remission‡ 55 76 42 20–69
CD 18 72 38 20–59
UC 36 78 44 24–69
A, alternating; C, constipation; CD, Cohn’s disease; D, diar-
rhoea; IBS, irritable bowel syndrome; IBD, inﬂammatory bowel
disease; M, mixed; U, unsubtyped; UC, ulcerative colitis.
* Precise ages were known for 99% of the total samples used.
† IBStype known for 97% of the total IBS samples used.
‡ CD/UC diagnosis known for 99% of the total IBD samples
used.
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Bacteroidetes, Actinobacteria, Tenericutes and Verruco-
microbia, covering 10 taxonomic bacterial classes and 36
genera (for more details on the bacterial targets for the
54 probes see Data S5).
Sample preparation and detection
The GA-test is based on regular molecular biology tech-
niques, comprising human faecal sample homogenisation
and mechanical bacterial cell disruption; automated total
bacterial gDNA extraction using magnetic beads; 16S
rRNA PCR DNA ampliﬁcation covering V3–V9; probe
labelling by single nucleotide extension; hybridisation to
complementary probes coupled to magnetic beads; and
signal detection using BioCode 1000A 128-Plex Analyzer
(Applied BioCode, Santa Fe Springs, CA, USA). The
method is described in detail in Data S2, and an over-
view to the whole process from sample preparation to
result is shown in Figure 2.
Data pre-processing
To ensure high quality assurance, several quality control
criteria were applied to the detection data for each sam-
ple: (i) a bead count >2 for each probe; (ii) the hybridi-
sation control (HYC) median signal >13 000; (iii) a
median background signal <500 and (iv) a universal con-
trol median signal >4500. Normalisation was applied by
ﬁrst dividing the signal intensity of each probe in each
sample by the signal intensity for HYC for that sample,
and multiplying by 1000. This was done to adjust for
sample differences due to pipetting or hybridisation.
Subsequently, normalisation to adjust for run differences
was applied by dividing the HYC-normalised signal of
each probe in each sample by the median HYC-norma-
lised signal of each probe for replicates of a synthetic
DNA control (Data S2; Table S1), and multiplying by
1000. Prior to normobiotic microbiota proﬁle calibration,
normalised signal intensities below 15 were set to 0 to
remove for low background noise and data was mean
centred. Test and validation samples were normalised,
and normalised signals below 15 were set to 0 before
data were mean centred using mean probe signals from
the normobiotic reference cohort.
Dysbiosis test development and validation
Principal component analysis (PCA)24 was used to build
a normobiotic microbiota proﬁle (model). The boundary
between nondysbiotic and dysbiotic was determined by
calculating conﬁdence regions for the values of Hotell-
ing’s T-square and Q statistics given by PCA scores in
the model. Geometrically this corresponds to a rectangle
with one corner located at the origin which classiﬁes
samples located within the rectangle as nondysbiotic
and samples located outside as dysbiotic. Analysis of
T-square and Q statistics scaled by the conﬁdence limit
showed that the Euclidian distance from the origin had a
log-normal like distribution (data not shown). Euclidian
In silico development of
highly specific probe-set
Fecal sample processing
Model calibration and
verification: development
of a DI algorithm
Test validation in healthy
IBS and IBD subjects
Algorithm-based read-out
DI>2 = dysbiosis
PCR
Labeling, hybridisation
and detection
gDNA from fecal samples of healthy volunteers
applied to GA-map technology platform
gDNA from fecal samples
applied to GA-map technology platform
Binding
Labeling
Generation of 
bacterial profile
1 2 3 4 5
Figure 2 | Flow chart illustrating the GA-map Dysbiosis Test development, starting with in silico development of
bacterial probe set, standardisation of laboratory analysis process, model calibration and veriﬁcation in healthy
individuals (normobiotic reference collection), and validation in healthy, IBS and IBD individuals. Derivation of a DI
based on bacterial 16S rRNA DNA analysis in faecal samples demonstrates that a DI score >2 conﬁrms microbiota
proﬁle deviations from the normobiotic reference collection.
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distance from the origin was used to merge the two
dimensions, and weighting was performed to capture the
effect of T-squared and Q statistics as appropriate. A sin-
gle numeric representation of the degree of dysbiosis,
deﬁned as the Dysbiosis Index (DI), was derived from a
log-normal distribution by assigning estimated portions
of the distribution to different values on a scale set from
0 to 5. A DI value of 2 was deﬁned as class separation
represented by the identiﬁed conﬁdence limits; a DI of 2
or lower being the nondysbiotic region and a DI of 3 or
higher being the dysbiotic region. The higher the DI
above 2, the more the sample is considered to deviate
from normobiosis, e.g. sample A with DI = 4 is farther
away from the normobiotic reference cohort in the
Euclidian space than sample B with DI = 3, thus A is
more dysbiotic than B. The scale was optimised with
emphasis on reducing technical variation between repli-
cates, meaning that the integer part of the numeric out-
put is decided by pre-determined levels of the Euclidian
distance.
To create the GA-test, 211 healthy individuals were
selected and randomly split into a training set (n = 165)
designed to build models and a test set (n = 46)
designed to tune parameters. Duplicate samples were
run, and mean normalised signal was used for training
and testing. Sample demographics for the two groups
were similar (Table 2). In addition, a set of IBS patients
were included in the test set (n = 127). A number of
models were developed and evaluated, and the frequency
of dysbiosis in the test set was used as measure of model
performance. For the ﬁnal PCA model, 15 principal
components were used, and a 98% conﬁdence limit was
determined for T-squared and Q statistics to deﬁne class
separation. When the model is used to score other sam-
ples, values outside these limits are deﬁned as dysbiotic.
External validation using an independent test set com-
prising healthy, IBS and IBD subjects (n = 287) was used
to assess the clinical diagnostic performance of the
model (Table 3). The validation set subjects were all
from unique donors who had not been included in the
healthy reference collection used for normobiotic proﬁle
calibration or in parameter tuning. Each sample was pro-
cessed using the ﬁnalised algorithm which converts data
for each sample into a single integer, i.e. the DI, which
represents the degree of dysbiosis based on bacterial
abundance and proﬁle within a sample relative to the
established normobiotic proﬁle. A DI > 2 represents a
potentially clinically relevant deviation in microbiotic
proﬁle from that of the normobiotic reference collection.
Finally, the dysbiosis frequency was calculated. In addi-
tion, PCA was performed on the validation set to investi-
gate differences in microbiota proﬁle between the three
subject groups.
Technical performance
The EU directive for in vitro diagnostic tests was fol-
lowed to ensure compliance with a CE-marked test.25
The main technical parameters evaluated were precision
and quantitative range of the test; both at probe signal
level and at ﬁnal output level (i.e. DI). At probe level,
precision of signals [coefﬁcient of variation [CV], %)
varied with raw signal intensity. Signals below 500 IU
were regarded as background noise; therefore, measure-
ment of variance was not applicable. For signals above
500 IU precision was estimated to be 8.4%, using
repeated runs for six donors over six faecal extractions
per donor over 2 days (n = 328). A CV below 10% was
Table 2 | Sample sets used for GA-map Dysbiosis Test
development and validation
Cohort
Samples,
n
Age,
mean
Female
(%)
Sample type, n
Healthy IBS IBD
Training 165 42 64 165 – –
Test 173 40 73 46 127 –
Validation 287 39 71 43 109 135
Full cohort 625 40 70 254 236 135
Table 3 | Percentage dysbiosis and mean DI score in
validation cohort
Cohort Total
Dysbiotic, %
(95% CI) DI, mean
Healthy controls 43 16 (11) 1.72
IBS 109 73 (8) 2.98
IBS-D 34 76 (14) 3.03
IBS-C 26 73 (17) 3.00
IBS-M 3 67 3.33
IBS-U 25 72 (18) 3.04
IBS-A 20 70 (20) 2.85
IBD treatment-na€ıve 80 70 (10) 3.31
CD 30 80 (14) 3.60
UC 50 64 (13) 3.14
IBD remission 55 80 (11) 3.15
CD 18 89 (14) 3.65
UC 36 75 (14) 2.92
A, alternating; C, constipation; CD, Crohn’s disease; D, diar-
rhoea; DI, Dysbiosis Index; IBD, inﬂammatory bowel disease;
IBS, irritable bowel syndrome; M, mixed; U, un-subtyped; UC,
ulcerative colitis.
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set as a criterion in development of the DI algorithm.
Based on repetitive measurements of 139 dysbiotic sam-
ples, 94% of the samples showed CVs below 10%. In
addition, several in-process test steps were evaluated
(data not shown).
Faecal microbiota variation over time
Variation in microbiota over time was investigated both
for normalised data across the selected probe set, and for
the test result (DI). Faecal samples were collected from
ﬁve donors (aged 24–38; 80% women) at a 1-week inter-
val for up to 14 weeks. PCA of normalised data was per-
formed, and statistical assessment of variation in the
signals for donor and sampling time (weekly) was con-
ducted using R package ffmanova, an implementation of
50–50 multivariate analysis of variance.26
Comparison to Illumina deep sequencing
To compare the performance of deep sequencing and
the GA-test data for the gut microbiota, a total of 188
samples from 162 subjects (89 healthy subjects and 73
IBS subjects; from the training and test cohorts described
in Table 2) were randomly selected. Sequencing was per-
formed using the paired-end 250 bp sequencing on the
Illumina MiSeq platform27 at the Norwegian High
Throughput Sequencing Center (UiO, Oslo, Norway).
Demultiplexed Illumina readings were clustered into
Operational Taxonomic Units (OTUs) using Qiime pipe-
line (v.1.7), StarCluster (http://star.mit.edu/cluster) and
Amazon Web Services (https://aws.amazon.com, virtual
machine identiﬁer ami-9bc9a7f2) at 97% sequence simi-
larity. Standard tools and parameters for Qiime down-
stream analysis were used, such as uclust for OTU
picking and Ribosomal Database Classiﬁer for taxonomy
assignment. A pre-deﬁned taxonomy map of reference
sequence OTU to taxonomy was used rather than open-
reference picking and assignment, as the reference data-
base of 16S rRNA sequences found in human gut is
comprehensive. Thereafter, one representative read for
each OTU group was extracted and aligned to create a
phylogenetic tree and an OTU Biological Observation
Matrix table was constructed (data not shown). The
OTU table was rareﬁed to 5000 sequences to remove
sample heterogeneity. Four samples which had less read
count than the set threshold were excluded from further
analysis.28
To compare the MiSeq sequence reads to the GA-map
Technology (GA-Technology, Genetic Analysis AS, Oslo,
Norway) probe signals, we identiﬁed probes that were
speciﬁc for a maximum of two species or genera, and
compared the normalised signals from the probes for
each sample to the number of sequences of the corre-
sponding sample and closest matching taxonomic bins
found by MiSeq sequencing. If a genus found by
sequencing corresponded to several probes, the sum of
the probes was used in the comparison, and if a probe
represented two genera the sum of sequences from both
genera was used. Finally, correlation between deep
sequencing data and GA-technology data was calculated
using Pearson correlation.
Furthermore, we applied the approach for deﬁning the
healthy reference collection, as described in the Dysbiosis
test development section, to the Illumina sequence data
set. In order to compare the results from this model with
GA-technology data, we constructed a new model using
GA-technology data limited to the same 188 samples.
The samples were classiﬁed either as dysbiotic or non-
dysbiotic using both models, and the results compared
by counting the number of samples that were classiﬁed
equally across the models.
Statistical analysis
All data were analysed at GA (Genetic Analysis AS).
Categorical data were expressed as the number of sub-
jects (and percentage) with a speciﬁed condition or clini-
cal variable, and the mean as appropriate. A test for
association between the two technologies were performed
using an independent t-test based on Pearson’s product
moment correlation coefﬁcient. The Mann–Whitney U-
test was used for testing DI values. All tests were two-
sided, and the chosen level of signiﬁcance was P < 0.05.
Analysis was done using the statistical computing lan-
guage R version 3.0.229 and MATLAB 2011b (The Math-
Works, Inc., Natick, MA, USA).
RESULTS
Frequency of dysbiosis in healthy, IBS and IBD
subjects
Validation of the developed GA-test was performed by
comparing frequency of dysbiosis in a set of 287 samples,
including healthy individuals previously not included in
the normobiotic proﬁle calibration (n = 43) and patients
with IBS (n = 109) and IBD (n = 135) (Table 2). The
results in the validation cohort are given in Table 3. Of
the 43 samples from healthy volunteers included in the
validation cohort, seven (16%) were determined as being
dysbiotic, with the distribution of DI scores for validation
cohort shown in Figure 3. Among the IBS patients, 80 of
109 (73%) were determined as being dysbiotic. In the
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IBD cohort, 100 of 135 (74%) were determined as being
dysbiotic, including 56 of 80 (70%) treatment-na€ıve IBD
patients, and 44 of 55 (80%) IBD patients in clinical
remission. The distribution of DI between IBS and IBD
patients was signiﬁcantly different (P < 0.01) and more
IBD patients than IBS patients had a DI >4 (Figure 3).
Furthermore, both in treatment-na€ıve IBD patients and
in IBD patients in remission, the frequency of dysbiosis
was higher in CD (80% and 89% respectively) than UC
(64% and 75%), with signiﬁcantly higher DI values in CD
than UC (P = 0.03).
The test was also applied to a set of 43 available sam-
ples from healthy volunteers from Denmark (n = 19;
aged 23–61; 63% women) and Spain (n = 24; aged 22–
56; 50% women). Seven of the 19 Danish samples were
determined as being dysbiotic with mean DI of 2.16,
resulting in 37% dysbiotic (95% CI, 22%) healthy vol-
unteers in this cohort. Among the Spanish samples, 10
of 24 were determined as being dysbiotic with mean DI
of 2.58, resulting in 42% dysbiotic (95% CI, 20%).
While the result for the Danish healthy cohort was not
signiﬁcantly different from the healthy validation samples
(P > 0.05), we observed that 50% (5/10) of the dysbiotic
samples in the Spanish samples showed a DI above 3.
Bacterial proﬁle in dysbiosis
Applying PCA to the validation cohort using normalised
data for all 54 probes demonstrated a relative clustering
of samples by disease cohorts. The scores for the ﬁrst
two principal components (PC), accounting for 48% of
the variance in the data, showed a tighter cluster for
healthy subjects in the bottom right corner compared
with a more diverse spread for subjects with IBD and
IBS (Figure 4a). The sample distribution in the scores
plot was found to be linked to the degree of dysbiosis,
with a central cluster of nondysbiotic samples sur-
rounded by samples with weak dysbiosis (DI = 3), and
the samples with the most severe dysbiosis (DI = 5)
scattered outside this cluster (Figure 4b). Both the ﬁrst
and second PC each separate the samples from healthy
volunteers from IBS and IBD samples to a certain
degree. The scatter of DI values implies that different
bacteria dominate dysbiosis for different samples. To
further investigate which bacterial groups were the main
contributors to dysbiosis in IBD and IBS, differences in
overall mean normalised signal between dysbiotic and
nondysbiotic status for each of the 54 probes were
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calculated. The pre-dominant bacteria contributing to
dysbiosis within the IBS cohort were Firmicutes (Bacilli),
Proteobacteria (Shigella/Escherichia), Actinobacteria and
Ruminococcus gnavus (Figure 5a). Similarly, the pre-
dominant bacteria within the IBD cohort were Proteo-
bacteria (Shigella/Escherichia), Firmicutes, speciﬁcally F.
prausnitzii, and Bacteroidetes (Bacteroides and Prevotel-
la) (Figure 5b). Interestingly, Proteobacteria (Shigella/
Escherichia) was among the top ﬁve dysbiosis-contribut-
ing bacterial groups for both IBS and IBD, implying
similarities in dysbiosis between IBS and IBD. However,
all bacterial groups that contributed most to dysbiosis in
the IBS cohort showed increased probe signal intensity
compared to nondysbiotic patients, while for the IBD
cohort, both reduced (F. prausnitzii) and increased
probe signal intensities were the main contributors to
dysbiosis.
We found a single probe with a differential signal
between samples from the Spanish and Scandinavian
cohorts (P < 0.01; Benjamini–Hochberg correction). The
probe targets Firmicutes (Streptococcus), and this signal
was found to be elevated in the Spanish samples com-
pared to the Scandinavian cohort. Figure 6 shows the
pre-dominant bacteria contributing to dysbiosis within
the Spanish samples. As expected, Proteobacteria (Shi-
gella/Escherichia) is again found to be a contributing
bacteria in dysbiosis. In addition, Bacteroides stercoris
and Biﬁdobacterium contribute to dysbiosis, which
potentially could be linked to differences, in e.g. diet
between Scandinavian countries and the Mediterranean
region.
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Faecal microbiota variation over time
Faecal samples were collected from ﬁve individuals at
1-week intervals for up to 14 weeks. PCA of the nor-
malised data (n = 64) revealed that most variability in
the longitudinal faecal microbiota analysis was related
to inter-individual variability; donors could clearly be
distinguished by the three-ﬁrst and most important
PCs in the score plot (Figure 7). The samples were
clustered according to faecal donor independently of
sample collection time. The three ﬁrst PCs described
65% of the total variability in the faecal microbiota
data.
The signiﬁcance of the PCs was analysed by ffmanova
and performed using normalised data with only the main
effects of donor and sampling time (weekly) included in
the model. The results show that the average amount of
variation between donors was greater than that within a
donor (P < 0.001) with explained variances based on
sums of squares of 0.48. The variation between sampling
time points was not signiﬁcant (P = 0.26), with
explained variances based on sums of squares of 0.11.
The low level of variation within one individual over
time is crucial in utilising the test for monitoring
changes during treatment for altering the microbiota
proﬁle.
Comparison to deep sequencing
The randomly selected set of 188 samples was sequenced
using MiSeq Illumina to investigate similarities with GA-
technology proﬁles. Any reads that did not match a ref-
erence sequence at greater than or equal to 97%
sequence identity were discarded according to a closed-
reference OTU-picking protocol. A total of 7 564 142
reads were binned into 254 OTUs at higher taxonomic
levels and 165 of these were identiﬁed at genus level. Of
the 165 genera, 77 were found in more than 10% of
samples.
After identifying the genera in the samples with MiSeq
sequencing, a comparison was performed with the closest
matching taxonomic bins detected by GA-technology.
In general, we found strong correlations between the
GA-technology signals and Qiime taxonomically
assigned MiSeq reads (Table 4), where Alistipes, Biﬁdo-
bacterium, Dialister, Lactobacillus/Pediococcus, R. gnavus
and Shigella/Escherichia all had a Pearson correlation of
r > 0.85. For some species the correlation was moderate,
e.g. B. fragilis (r = 0.38), Ruminococcus albus/bromii
(r = 0.31) and Streptococcus sanguinis/thermophilus
(r = 0.49). However, since MiSeq sequencing did not
PCA Scoresplot
PC2 (17.9%)
PC1 (34.0%)
PC3 (12.7%)
Figure 7 | Scores for the ﬁrst three principal
components from PCA of normalised data from ﬁve
healthy subjects collected weekly for up to 14 weeks
(n = 64). One point is one sample for donor x taken
at time point y. The ﬁrst three PCs account for 65%
of the variation, and points are coloured according
to donor.
Table 4 | Correlation between normalised GA-map
signal data and MiSeq Illumina sequence data (97%
sequence identity) for 188 healthy and IBS samples
Taxonomic group
Correlation
coefﬁcient (r)* P-value
Mycoplasma hominis† 0.05 0.50
Ruminococcus albus/bromii‡ 0.31 <0.001
Bacteroides fragilis‡ 0.38 <0.001
Streptococcus sanguinis/thermophilus‡ 0.49 <0.001
Phascolarctobacterium 0.72 <0.001
Faecalibacterium prausnitzii 0.75 <0.001
Streptococcus thermophilus 0.78 <0.001
Akkermansia 0.79 <0.001
Eubacterium 0.79 <0.001
Megashera/dialister 0.83 <0.001
Ruminococcus gnavus 0.86 <0.001
Dialister 0.88 <0.001
Alistipes 0.90 <0.001
Biﬁdobacterium 0.90 <0.001
Shigella/Escherichia 0.93 <0.001
Lactobacillus/Pediococcus 0.94 <0.001
* Correlation coefﬁcients were determined for the closest
matching taxonomic bins.
† Mycoplasma only identiﬁed in one sample by MiSeq Illumina
sequencing.
‡ Illumina sequencing did not enable selective detection of
species.
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allow for detection at species level, a direct comparison
to the speciﬁc probe signals can be complicated if the
speciﬁc species is not the dominating species in a genera.
Interestingly, no correlation was found between the two
methods for the species Mycoplasma hominis
(r = 0.05). Using MiSeq sequencing, Mycoplasma
genus was only detected in one sample, implying that
MiSeq sequencing does not allow for the selective detec-
tion of this genus at all. In contrast, M. hominis was
detected in a majority of the 188 samples with the GA-
technology. The highly speciﬁc GA-technology probe
detecting M. hominis binds to V6 on the 16S rRNA
gene, a variable region not covered by MiSeq Illumina
sequencing (Figure 1).
In addition, two new models were built using Illu-
mina sequencing data and GA-technology probe inten-
sity data with eight and nine PCs, respectively. The
number of PCs was selected by optimising the fre-
quency of dysbiosis in test samples (at the most 20% of
healthy individuals and 60% of IBS patients were deter-
mined as dysbiotic). The training data set consisted of
100 samples from healthy volunteers, and the test set
included 15 healthy and 73 IBS samples. The results
were compared across the two models and yielded 80%
concordance.
DISCUSSION
In this article, we demonstrate the performance of a
novel gut microbiota test, aiming to identify and cha-
racterise dysbiosis by determining deviation from nor-
mobiosis. Such a diagnostic approach contrasts to direct
diagnosis of a particular disease. Characteristic sets of
bacteria are required in a healthy normobiotic gut micro-
biota, and deviation will represent a dysbiotic state.
Quantitative measurement of deviation in bacterial mic-
robiota makes it possible to characterise dysbiosis in
samples from IBS and IBD patients based on a single
diagnostic algorithm targeting normobiosis.
Ideal enabling technologies will be those that can pro-
ﬁle the microbiome as a whole and, at the same time,
reliably target deviations (and their degree) from normo-
biosis. Notably, gut microbiota also harbour a range of
transient colonisers with no diagnostic value that have
the potential to generate obscure diagnostic results. Fur-
thermore, recent evidence suggests that species-level
information is important in gut microbiota diagnostics.30
Techniques with a low error rate which target a wide
range of variable positions in the 16S rRNA gene would
therefore be preferable for discriminating between nor-
mobiosis and dysbiosis.
The present test is a broad-spectrum, reproducible,
precise, high throughput, easy to use method of quanti-
fying the extent of dysbiosis that is especially suitable for
clinical use. This test gives an algorithmically derived DI
based on bacterial abundance and proﬁle within a sam-
ple. This DI is an indicator of the degree to which an
individual’s microbiome deviates from that of a healthy
reference collection and could potentially be highly rele-
vant in clinical diagnosis and monitoring of the progres-
sion of conditions such as IBD and IBS. The stability of
the human gut microbiota is another important feature
if microbial characterisation is to play a role in diagnosis,
treatment and prevention of disease. Faith et al.31
showed that, in an individual’s microbiota, 60% of the
bacterial strains persisted over the course of 5 years. Our
data also suggest that there is little variation in an indi-
vidual’s gut microbiota over time, since we found only a
low within individual variation in weekly sampling over
14 weeks.
High-throughput sequencing is an excellent tool for
exploratory analyses of the gut microbiota, and is widely
used. A limitation to this technology is the relatively
short read-lengths used for sequencing, only allowing for
a limited region of the 16S rRNA gene to be exploited
(usually V3 and/or V4) (Figure 1); thus, less than 50%
of obtained sequences can be annotated at genus level.32
The lack of detection of Mycoplasma with MiSeq Illu-
mina sequencing, detected in a majority of the samples
using a probe targeting V6 with the GA-map test, fur-
ther illustrates the limitations of using only limited vari-
able regions of the 16S rRNA gene. Moreover, since
MiSeq sequencing does not allow for detection at species
level, a direct comparison to the speciﬁc probe signals
can be challenging if the speciﬁc species is not the domi-
nating species in a genera. Even so, it is possible to gain
important insights to an individuals’ gut microbiota
using high-throughput sequencing. Compared to the
GA-technology, this technology is superior towards
exploring novel bacterial biomarkers, and gaining in-
depth information regarding all bacteria present in a
sample. However, in terms of the human gut microbiota,
the main patterns have been explored,32 and GA-tech-
nology has consolidated on this information in designing
54 highly speciﬁc DNA probes exploiting a broad range
of gene variability (V3–V7). These 54 probes have fur-
ther been converted into a diagnostic test but without
the laborious data-analysis required following high-
throughput sequencing. Therefore, the GA-technology
provides a unique opportunity to study changes in
gut microbiota proﬁles potentially associated with
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gastrointestinal-related disorders. Our results show agree-
ment between the two technologies regarding determin-
ing dysbiosis, as well as strong correlations in detecting
several bacteria. However, results also show weak corre-
lations for some speciﬁc species, possibly due to lack of
selective species detection by MiSeq Illumina sequencing.
The GA-test identiﬁes a high frequency of dysbiosis
in IBS and IBD patients and low frequency in healthy
individuals. Both IBD patients in remission and treat-
ment-na€ıve IBD patients reported DI scores well above
the threshold of two with a dysbiosis frequency of 80%
and 70%, respectively. IBS patients, deﬁned according
to Rome II and III-criteria (depending on collection
site), showed a dysbiosis frequency of 73%, conﬁrming
previous observations,30, 33, 34 while the frequency of
dysbiosis in healthy individuals was 16%. The normobi-
otic reference collection comprised healthy Scandinavian
individuals, which may be a potential limitation of the
test. We found slightly increased DI in healthy controls
from Denmark (DI ≥ 3 in 33%, n = 19) and Spain
(DI ≥ 3 in 42%, n = 24); however, the sample size is
too small to allow any deﬁnitive conclusions to be
drawn regarding differences in frequency of dysbiosis or
microbiota between the populations. Further investiga-
tion is needed with increased sample numbers from
across Europe to ﬁrmly establish the broad clinical util-
ity of the test.
The intestinal microbiome is a dynamic environment
in which the relative balance of the composition of pro-
and anti-inﬂammatory bacterial species is known to be
highly relevant.35 For example, the microbial signature of
Firmicutes species present in the intestinal tract in
patients with UC differs signiﬁcantly from that in CD
patients.36 Compared with CD patients in long-term
remission, patients with relapsing CD have lower levels
of all Firmicutes species, and a bacterial proﬁle signiﬁ-
cantly predictive of relapse for up to 1 year before inﬂix-
imab withdrawal.17
Dysbiosis is associated with many diseases, including
IBS, IBD, obesity and diabetes,4–8 and has also been impli-
cated in depression and autism.37, 38 In recent years, new
treatment options have emerged with respect to restoring
the balance of the microbiota in dysbiotic patients. FMT
is now regarded as the most effective treatment in relaps-
ing Clostridium difﬁcile colitis,18, 39 and is currently being
studied in phase I to IV clinical trials in many of the afore-
mentioned conditions (CD, phase II/III NCT01793831;
UC, phase I NCT01947101, phase II NCT01896635, phase
II/III NCT01790061; IBD including CD and UC, phase IV
NCT02033408). A key barrier in the interpretation of
FMT data has been the variability in bacterial composition
of donor microbiota, not only related to pathogenic
organisms but also to the composition of the normally
occurring microbiota, further highlighting the importance
of identifying a method to sufﬁciently characterise both
pathogenic and nonpathogenic microbes. The ability to
characterise an individual’s microbiome and monitor
alterations may allow for the prediction of therapeutic
outcome or even relapse in such conditions.17 It may also
help to explain why a patient is refractory to particular
therapeutic regimens and aid adaptation of the regimen
accordingly. Furthermore, rapid and reproducible detailed
bacterial proﬁles from normobiotic and dysbiotic individ-
uals may aid the continuation of innovative therapeutic
approaches such as FMT.18 Thus, use of the test could
prove clinically useful in determining dysbiosis, not only
in IBS and IBD patients, but also in other conditions
where knowledge about the microbiota proﬁle might
prove clinically useful, in the subsequent monitoring of
prescribed treatment regimens, and in the evolution of
new therapeutic approaches.
In conclusion, this is the ﬁrst clinical test, aiming to
identify and characterise dysbiosis based on faecal speci-
mens. The diagnostic applicability of the test will have to
await further clinical experience, also from international
studies, as one might expect geographical deviations
related to microbial patterns. Nevertheless, the present
standardised and reproducible method represents, in par-
ticular, a step forward as a combined practical, ready to
use, clinical and research tool. The method will allow us
to gain more knowledge on the microbial component of
intestinal disorders, and in general, provide the possibil-
ity of increasing our understanding of the part played by
the microbiome in the disease process.
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